DOCSLIB.ORG

Development of Chromatographic Method for Determination of Drugs Reducing Cholesterol Level

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of Chromatographic Method for Determination of Drugs Reducing Cholesterol Level Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 69 No. 1 pp. 139ñ143, 2012 ISSN 0001-6837 Polish Pharmaceutical Society DEVELOPMENT OF CHROMATOGRAPHIC METHOD FOR DETERMINATION OF DRUGS REDUCING CHOLESTEROL LEVEL ELØBIETA KUBLIN1, EWA MALANOWICZ1, BARBARA KACZMARSKA-GRACZYK1 and ALEKSANDER P. MAZUREK1,2 1 Department of Basic and Applied Pharmacy, National Medicines Institute, 30/34 Che≥mska St., 00-725 Warszawa, Poland 2 Department of Drug Chemistry, Medical University of Warsaw, 1 Banacha St., 02-097 Warszawa, Poland Keywords: hyperlipidemia, HPLC, GC, aryloxyalkylcarboxylic acids derivatives, 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors (HMG-CoA), fenofibrate, ciprofibrate, bezafibrate, gemfibrozil, atorvastatin calcium, fluvastatin sodium, rosuvastatin calcium, lovastatin, simvastatin Hyperlipidemia (HLP) is a group of lipid aryloxyalkylcarboxylic acids. This class of drugs metabolism disorders with various pathogenesis. Its include new generation drugs: bezafibrate, ciprofi- characteristic feature is an increase in cholesterol brate, etofibrate, fenofibrate and gemfibrozil (1ñ4). level, especially the low density lipoprotein fraction The available literature of the last several years (LDL) level or triglyceride level in blood. An includes several publications describing separately increase in total and LDL cholesterol level is related an identification and determination of lovastatin to the increased risk of ischemic heart disease as derivatives and derivates of aryloxyalkylcarboxylic well as cerebral, coronary and peripheral circulation acids in pharmaceutical products and biological disorders. material. HPLC or UPLC methods with octadecyl The medications against hyperlipidemia and packed column with UV-VIS detector (11, 13ñ16) cholesterol level reduction are 3-hydroxy-3-methyl- and mass detector (12), the capillary electrophoresis glutaryl-coenzyme A reductase inhibitors (HMG- (9) and electrochemical methods ( 7) are used for CoA) also known as statins and aryloxyalkylcar- statins analysis. boxylic acid derivatives, also known as fibrates. The tests on fibrates relied mainly on the Statins inhibit biosynthesis of endogenous choles- HPLC method with Symmetry ODS or Hypersil terol at the mevalonic acid synthesis level and ODS columns using a spectrophotometric detector reduce of total cholesterol, LDL fraction and triglyc- (12) or mass spectrometry (10, 12), the method of erides levels in plasma and increases HDL fraction capillary electrophoresis (6) and gas chromatogra- level. A mother compound for a group of 3- phy with mass spectrometry detector (12). hydroxy-3-methylglutaryl-coenzyme A reductase In 2006, E. Kublin et al. have published a study inhibitors (HMG-CoA) is lovastatin. Currently, a on the determination of all statins by gas chro- semi-synthetic derivatives are available (simvastatin matography with FID detector (5). and pravastatin sodium), as well as synthetic com- In 2010, a study on determination of all drugs pounds ñ atorvastatin calcium, fluvastatin sodium (fibrate group) with a single column and a uniform and lately rosuvastatin calcium (1ñ4). methodology (HPLC with Symmetry C18 column The fibrates inhibit VLDL lipoprotein synthe- and spectrophotometric detector) has been pub- sis in liver and accelerate catabolism by increasing lished by the same authors (17). In the Department lipoprotein lipase activity. Also they improve HDL of Basic and Applied Pharmacy, National Medicines level and affect the return of cholesterol. A clofi- Institute, a determination method for all statin class brate is a mother compound of the derivatives of drugs by HPLC with Symmetry C18 column and * Corresponding author: e-mail: [email protected] 139 140 ELØBIETA KUBLIN et al. Table 1. Retention time Rf for the tested compounds (HPLC). Table 2. Retention time Rf for the tested compounds (GC). CHEMICAL NAME RETENTION TIME CHEMICAL NAME RETENTION TIME [min] [min] ROSUVASTATIN CALCIUM 2.4 CIPROFIBRATE 1.6 BEZAFIBRATE 2.8 GEMFIBROZIL 2.9 ATORVASTATIN CALCIUM 3.3 FENOFIBRATE 7.1 FLUVASTATIN SODIUM 3.6 BEZAFIBRATE 7.4 CIPROFIBRATE 3.9 LOVASTATIN 9.6 GEMFIBROZIL 6.1 SIMVASTATIN 9.9 LOVASTATIN 7.5 ATORVASTATIN 11.4 CALCIUM SIMVASTATIN 9.8 FENOFIBRATE 13.3 Table 3. Statistical assessment of the results of simultaneous determination of active substances content in the drugs by HPLC. COMPOUND/PRODUCT NO. OF TOTAL STANDARD CONFIDENCE RSD NAME SAMPLES AVERAGE X DEVIATIONS INTERVAL X ± ∆X (%) n (%) Pu = 95% (%) Atorvastatin calcium ñ tablets (Corator) 6 100.55 0.90 100.55 ± 0.86 0.90 Fenofibrate ñ capsules (Lipanthyl) 6 102.47 0.83 102.47 ± 0.79 0.81 Simvastatin ñ tablets (Zifam) 6 95.90 0.99 95.90 ± 0.94 1,03 Fenofibrate ñ capsules (Lipanthyl) 6 99.48 1,51 99.48 ± 1.44 1,52 Figure 1. Atorvastatin calcium/fenofibrate solution chromatogram Figure 2. Simvastatin/fenofibrate solution chromatogram (at 238 (at 246 nm). nm) Development of chromatographic method for determination of... 141 spectrophotometric detector was developed and is which could be applied to analyze the complete currently in print. class of 3-hydroxy-3-methylglutaryl-coenzyme A The available literature of the last several years reductase inhibitors (HMG-CoA) and aryloxyalkyl- includes a single publication on simultaneous deter- carboxylic acid derivatives in routine analysis and to mination of cholesterol level reducing drugs (3- assess its analytical and economical aspects. hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ñ HMG-CoA) i.e., statins and ary- EXPERIMENTAL loxyalkylcarboxylic acid derivatives i.e., fibrates. The authors applied a HPLC test method with mass Reference materials sensitive detector (8). Rosuvastatin calcium (Zentiva), atorvastatin A combination of selected statin and fibrate calcium (Biocon Ltd.), simvastatin (Ph. Eur.), lovas- class drugs are applied in modern treating hypocho- tatin, pravastatin sodium, fluvastatin sodium fenofi- lesterolemia. The most common combination is brate CRS (Ph. Eur.), bezafibrate (KRKA), etofi- fenofibrate (100 mg to 267 mg/day) and simvastatin brate (Merz Co. GmbH), ciprofibrate (Sanofi (10ñ80 mg/day) or atorvastatin calcium (10ñ80 Chimie), gemfibrozil (Egis Ltd.), clofibrate (ICI). mg/day). A simultaneous determination of most commonly used drugs is presented in the study. Medical products A purpose of this study was to develop a sim- Corator ñ coated tablets 40 mg ple, sensitive and unified quantification method, (PrzedsiÍbiorstwo Farmaceutyczne LEK-AM), Zifam ñ coated tablets 20 mg (Polfa Warszawa S.A.), Lipanthyl ñ capsules 100 mg (Laboratoires Fourier). Reagents and apparatus High purity HPLC reagents: acetonitrile, methanol (Rathburn), 85% orthophosphoric acid (AppliChem), Dionex liquid chromatograph with spectrophotometric detector and Agilent Technologies 6890N gas chromatogram with FID detector. High performance liquid chromatography (HPLC) Simultaneous quantification of atorvastatin and fenofibrate Drugs: Corator and Lipanthyl. The determina- tion was carried out at 246 nm for atorvastatin calci- Figure 3. Chromatogram of the mixture statins + fibrates (HPLC) um and at 286 nm for fenofibrate. Figure 4. Chromatogram of the mixture statin/fibrate (GC) 142 ELØBIETA KUBLIN et al. Preparation of standard solutions: Ca. 5 mg of mobile phase: ACN : water (70:30, v/v), at pH = 2.5; reference material (atorvastatin calcium) and 25 mg column temperature: 35OC, autosampler tempera- of reference material (fenofibrate) was transferred to ture: 15OC, mobile phase flow rate: 1.2 mL/min, a 100 mL flask, dissolved in methanol and diluted to injection volume: 10 µL, wavelength: 238 nm. volume with methanol. All tested compounds were separated (Table 1 Preparation of tested solutions: Ca. 220 mg of shows the retention times). Separation factor powdered Corator tablets (ca. 20 mg of active sub- between two adjacent peaks (fluvastatin and ciprofi- stance ñ atorvastatin calcium) and 250 mg of brate ñ peak 4 and 5, Fig. 3, is 2.30. Fig. 3 shows an Lipanthyl coated tablets (ca. 100 mg of active sub- example chromatogram. stance ñ fenofibrate) was transferred to a 50 mL A mixture of the following substances with flask, approx. 40 mL of methanol was added and methanol was used (GC method): atorvastatin calci- shaken by mechanical means for 30 min. The solu- um ñ 5.94 mg/mL, lovastatin ñ 1.56 mg/mL, sim- tion was diluted to volume with methanol and fil- vastatin ñ 1.48 mg/mL, fenofibrate ñ 1.42 mg/mL, tered. Two and a half mL of the solution was dilut- ciprofibrate ñ 5.96 mg/mL, bezafibrate ñ 4.88 ed to 20 mL with methanol. Figure 1 shows an mg/mL and gemfibrozil ñ 1.34 mg/mL. example chromatogram, Table 3 shows the results The following identification conditions were and statistical assessment. developed: column HP ñ 1; 30 m ◊ 0.25 mm ◊ 0.25 µm; detector temperature: 320OC, injection chamber Simultaneous quantification of simvastatin and temperature: 300OC, column temperature: program ñ fenofibrate initial temperature 190OC for 1 min; increment Drugs: Zifam and Lipanthyl. The determina- 10OC/1 min to final temperature 280OC, 2 min, gas tion was carried out at 238 nm for simvastatin and flow: 2.9 mL/min, injection volume: 1,0 µL, split: 286 nm for fenofibrate. 10:1. Preparation of standard solutions: Ca. 5 mg of All tested compounds were separated. Table 2 reference material (simvastatin) and 25 mg of refer- shows the retention times. Separation factor ence material (fenofibrate) was transferred to a 100 between two adjacent peaks (fenofibrate and bezafi- mL flask, dissolved in methanol and diluted to
Load more

Recommended publications
  • FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy by Anthony C
    Supplement to Supported by an unrestricted educational grant from Abbott Laboratories March/April 2008 FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy By Anthony C. Keech, MBBS, Msc Epid, FRANZCS, FRACP; and Paul Mitchell, MBBS(Hons), MD, PhD, FRANZCO, FRACS, FRCOphth, FAFPHM This agent’s mechanism of benefit in diabetic retinopathy appears to go beyond its effects on lipid concentration or blood pressure, and this potential mechanism of action operates even when glycemic control and blood pressure levels are within goal. ABSTRACT icant relative reduction was seen of almost one-third in PURPOSE the rate of first laser application for retinopathy after The FIELD (Fenofibrate Intervention and Event an average treatment duration of 5 years with fenofi- Lowering in Diabetes) study sought to investigate brate 200 mg/day. whether long-term lipid-lowering therapy with fenofi- In this report, we detail the effects of fenofibrate brate would reduce macro- and microvascular compli- administration on ophthalmic microvascular compli- cations among patients with type 2 diabetes. We previ- cations and attempt to clarify some of the underlying ously reported that in type 2 diabetes patients with pathologies being addressed among patients undergo- adequate glycemic and blood pressure control, a signif- ing laser treatment. Jointly sponsored by The Dulaney Foundation and Retina Today MARCH/APRIL 2008 I SUPPLEMENT TO RETINA TODAY I 1 FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and Retina Today. Release date: April 2008. Expiration date: April 2009. This continuing medical education activity is supported by an unrestricted educational grant from Abbott Laboratories.
    [Show full text]
  • Profile Profile Uses and Administration Adverse Effects And
    Etacrynic Acid/Ezetimibe 1379 unchanged and partly in the form of metabolites. It is Efortil; Etilefril; Chile: Elfortilt; Fin.: Elfortil; Fr.: Effortil; Ger.: over 10 years, may be given ezetimibe for the same indica­ extensively bound to plasma proteins. Bioflutin; Effortil; Etil; Pholdyston; Thomasin; Gr.: Effortil; tions and at the same doses as in adults (see above). ' Efortil; Ita/. : Elfortil; Jpn: Effortil; Mex.: Effortil; Quimtatil; Pol.: Effortil; Port.: Effortil; S.Afr.: Effortilt; Spain: Efortil; Swed.: Hyperlipidaemias. Ezetimibe inhibits the absorption of �:.�!?.�.��.!��-��--·········································································· Effortil; Switz. : Effortil; Thai.: Buracard; Circula; Circuman; dietary cholesterol' and, although there is a compensatory Proprietary Preparations (details are given in Volume B) Venez. : Elfortilt; Effrine; Efxine; Hyposia; Hyprosiat; Effontil. increase in cholesterol synthesis in the liver.' overall Single-ingredient Preparations. Austral.: Edecrin; Canad.: Multi-ingredient Preparations. Austria: Agilan; Amphodynt; plasma LDL-cholesterol concentrations are reduced.2 Ezeti­ Edecrin; Hung.: Uregyt; Ita!. : Reomax; Rus.: Uregyt (Ypei"HT); Effortil camp; Hypodynt; Influbenet; Ger.: Dibydergot plus; mibe may be used alone' in the management of hyperlipi­ Ukr.: Uregyt (YperHT); USA: Edecrin. Effortil plust; Switz.: Dibydergot plust; Elfortil plust. daentias (p. 1248.1) but use with lipid regulating drugs Phannacopoeial Preparations that act by reducing cholesterol synthesis may
    [Show full text]
  • Joint Assessment Report Was Discussed by the Phvwp at Its Meeting in July 2007 and Finalised in September 2007
    ASSESSMENT REPORT on the benefit:risk of fibrates EXECUTIVE SUMMARY 1. BACKGROUND In the light of the established role of statins in the primary and secondary prevention of cardiovascular disease (CVD) and safety concerns arising from the use of fibrates, the CHMP Pharmacovigilance Working Party (PhVWP) agreed to undertake a benefit:risk assessment of this class of medicines. The objective was to establish the current place of fibrates in the treatment of cardiovascular and dyslipidaemic diseases, and in diabetes mellitus; also to provide recommendations regarding amendments of the Summary of Product Characteristics (SPC), as necessary. Fibrates exert their effects mainly by activating the peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Unique in this class, bezafibrate is an agonist for all three PPAR isoforms alpha, gamma, and delta. Fibrates have been shown to reduce plasma triglycerides by 30% to 50% and raise the level of high density lipoprotein cholesterol (HDL- C) by 2% to 20%. Their effect on low density lipoprotein cholesterol (LDL-C) is variable, ranging from no effect to a small decrease of the order of 10%. Today there are four licensed fibrates: bezafibrate, fenofibrate, gemfibrozil and ciprofibrate. Their currently approved indications are quite broad and in many cases still use the old Fredrickson classification for dyslipidaemias. 2. METHODOLOGY In February 2006 a List of Questions was agreed by the PhVWP for the Marketing Authorisation Holders (MAHs) of medicinal products containing one of the four currently licensed fibrates (Annex 1). Other clofibrate-containing medicinal products (e.g. etofibrate, etofyllinclofibrate) were excluded from this class review, since these are available only in a few member states via national marketing authorizations.
    [Show full text]
  • Fenofibrate Capsules Apotex Standard 67 Mg and 200 Mg
    PRODUCT MONOGRAPH PrAPO-FENO-MICRO Fenofibrate Capsules Apotex Standard 67 mg and 200 mg PrAPO-FENOFIBRATE Fenofibrate Capsules Apotex Standard 100 mg Lipid Metabolism Regulator APOTEX INC. 150 Signet Drive Toronto, Ontario DATE OF REVISION: M9L 1T9 October 7, 2014 Control No.: 169773 - 1 - PRODUCT MONOGRAPH PrAPO-FENO-MICRO Fenofibrate Capsules Apotex Standard 67 mg and 200 mg PrAPO-FENOFIBRATE Fenofibrate Capsules Apotex Standard 100 mg THERAPEUTIC CLASSIFICATION Lipid Metabolism Regulator ACTIONS AND CLINICAL PHARMACOLOGY Fenofibrate lowers elevated serum lipids by decreasing the low-density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fenofibrate increases the high density lipoprotein (HDL) cholesterol fraction. Fenofibrate appears to have a greater depressant effect on the VLDL than on the low density lipoproteins (LDL). Therapeutic doses of fenofibrate produce elevations of HDL cholesterol, a reduction in the content of the low density lipoproteins cholesterol, and a substantial reduction in the triglyceride content of VLDL. The mechanism of action of fenofibrate has not been definitively established. Work carried out to date suggests that fenofibrate: · enhances the liver elimination of cholesterol as bile salts; · inhibits the biosynthesis of triglycerides and enhances the catabolism of VLDL by increasing the activity of lipoprotein lipase; · has an inhibitory effect on the biosynthesis of cholesterol by modulating the activity of HMG- CoA reductase. Metabolism and Excretion After oral administration with food, fenofibrate is rapidly hydrolyzed to fenofibric acid, the active metabolite. In man it is mainly excreted through the kidney. Half-life is about 20 hours. In patients with severe renal failure, significant accumulation was observed with a large increase in half-life.
    [Show full text]
  • Methods of Chromatographic Determination of Medicines Decreasing the Level of Cholesterol
    Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 67 No. 5 pp. 455ñ461, 2010 ISSN 0001-6837 Polish Pharmaceutical Society ANALYSIS METHODS OF CHROMATOGRAPHIC DETERMINATION OF MEDICINES DECREASING THE LEVEL OF CHOLESTEROL ELØBIETA KUBLIN1, BARBARA KACZMARSKA-GRACZYK1, EWA MALANOWICZ1 and ALEKSANDER P. MAZUREK1,2 1Department of Basic and Applied Pharmacy, National Medicines Institute, 30/34 Che≥mska St., 00-725 Warszawa, Poland 2Department of Drug Chemistry, Medical University of Warsaw, 1 Banacha St., 02- 097 Warszawa, Poland Abstract: With reference to common application of HPLC to routine analytical tests on medicinal products decreasing the level of cholesterol, including three compounds from this group ñ fenofibrate, bezafibrate and etofibrate, we developed a new method for determining two other compounds ñ ciprofibrate and gemfibrozil. The developed HPLC method may be used for identification and qualitative determination of selected com- pounds ñ derivatives of aryloxyalkylcarboxylic acids as well as it may be used for simultaneous separation and determination of all compounds from the group of fibrates using one column and the same methodology. The results and statistical data indicate good sensitivity and precision. The RSD value presented is equivalent to the newly developed method of determinination of ciprofibrate and gemfibrozil in the substances and medicinal products ñ capsules and coated tablets. Keywords: hyperlipidemia, HPLC, derivatives of aryloxyalkylcarboxylic acids, bezafibrate, ciprofibrate, fibrate, gemfibrozil, etofibrate, clofibrate Hyperlipidemia (HLP) is a group of disorders The selected medicines applied in the treat- in the lipid balance of various pathogenesis, which ment of hyperlipidemia, particularily leading to a demonstrate an increase in the cholesterol concen- decrease in the level of cholesterol, have been apart tration, mostly the level of lipoprotein fractions of from statins, the derivatives of aryloxyalkyl-car- low density (LDL) and/or the concentration of boxylic acids ñ so called fibrates.
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Therapeutic Class Overview Fibric Acid Derivatives
    Therapeutic Class Overview Fibric Acid Derivatives Therapeutic Class • Overview/Summary: The fibric acid derivatives are agonists of the peroxisome proliferator activated receptor α (PPARα). Activation of PPARα increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein CIII. The resulting decrease in triglycerides (TG) produces an alteration in the size and composition of low- density lipoprotein cholesterol (LDL-C) from small, dense particles to large buoyant particles. There is also an increase in the synthesis of high-density lipoprotein cholesterol (HDL-C), as well as apoprotein AI and AII.1-10 The major action of this class of medications is to reduce TG. The fibric acid derivatives can decrease TG by 20 to 50% and increase HDL-C by 10 to 35%. They also lower LDL- C by 5 to 20%; however, in patients with hypertriglyceridemia, LDL-C may increase with the use of fibric acid derivatives.11 Several fenofibrate products are currently available, including micronized and non-micronized formulations. The different fenofibrate formulations are not equivalent on a milligram-to-milligram basis. Micronized fenofibrate is more readily absorbed than non-micronized formulations, which allows for a lower daily dose. Fenofibrate (micronized and non-micronized formulations), fenofibric acid, and gemfibrozil are available generically in at least one dosage form and/or strength.12 Fenofibrate and fenofibric acid are Food and Drug Administration (FDA)-approved for the treatment of hypercholesterolemia and mixed dyslipidemias, as well as hypertriglyceridemia. Gemfibrozil is FDA- approved for the treatment of hypertriglyceridemia and to reduce the risk of developing coronary heart disease (CHD) in select patients.13 Gemfibrozil has demonstrated a reduction in the risk of fatal and nonfatal myocardial infarction (MI) for primary prevention, as well as a reduction in CHD death and nonfatal MI and stroke for secondary prevention.
    [Show full text]
  • Peroxisome Proliferator-Activated Receptors
    PPAR Peroxisome proliferator-activated receptors PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism. www.MedChemExpress.com 1 PPAR Inhibitors, Agonists, Antagonists, Activators & Modulators 13-Oxo-9E,11E-octadecadienoic acid 15-Deoxy-Δ-12,14-prostaglandin J2 Cat. No.: HY-N5097 (15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2) Cat. No.: HY-108568 13-Oxo-9E,11E-octadecadienoic acid, an isomer of 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a 9-oxo-ODA, is a potent PPARα activator derived cyclopentenone prostaglandin and a metabolite of from tomato juice. 13-Oxo-9E,11E-octadecadienoic PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a acid decreases plasma and hepatic triglyceride in selective PPARγ (EC50 of 2 µM) and a covalent obese diabetic mice. PPARδ agonist. Purity: >98% Purity: ≥96.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg 4-O-Methyl honokiol 5-Aminosalicylic Acid Cat. No.: HY-U00450 (Mesalamine; 5-ASA; Mesalazine) Cat. No.: HY-15027 4-O-Methyl honokiol is a natural neolignan 5-Aminosalicylic acid (Mesalamine) acts as a isolated from Magnolia officinalis, acts as a specific PPARγ agonist and also inhibits PPARγ agonist, and inhibtis NF-κB activity, used p21-activated kinase 1 (PAK1) and NF-κB.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0155091A1 Huval Et Al
    US 2002O155091A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0155091A1 Huval et al. (43) Pub. Date: Oct. 24, 2002 (54) COMBINATION THERAPY FOR TREATING Publication Classification HYPERCHOLESTEROLEMIA (51) Int. Cl." ..................................................... A61K 31/74 (75) Inventors: Chad Cori Huval, Somerville, MA (US); Stephen Randall Holmes-Farley, (52) U.S. Cl. .......................................................... 424/78.29 Arlington, MA (US); John S. Petersen, Acton, MA (US); Pradeep K. Dhal, Westford, MA (US) (57) ABSTRACT Correspondence Address: HAMILTON, BROOK, SMITH & REYNOLDS, The invention relates to methods for treating hypercholes P.C. terolemia and atherosclerosis, and reducing Serum choles 530 VIRGINA ROAD terol in a mammal. The methods of the invention comprise P.O. BOX 91.33 administering to a mammal a first amount of a bile acid CONCORD, MA 01742-9133 (US) Sequestrant compound which is an unsubstituted polydial lylamine polymer and a Second amount of a cholesterol (73) Assignee: GelTex Pharmaceuticals, Inc., lowering agent. The first and Second amounts together Waltham, MA comprise a therapeutically effective amount. (21) Appl. No.: 10/025, 184 The invention further relates to pharmaceutical composi tions useful for the treatment of hypercholesterolemia and (22) Filed: Dec. 19, 2001 atherOSclerosis, and for reducing Serum cholesterol. The pharmaceutical compositions comprise a combination of a Related U.S. Application Data first amount of an unsubstituted polydiallylamine polymer compound and a Second amount of a cholesterol-lowering (63) Continuation of application No. 09/311,103, filed on agent. The first and Second amounts comprise a therapeuti May 13, 1999, now Pat. No. 6,365,186, which is a cally effective amount.
    [Show full text]
  • Section B Changed Classes/Guidelines Final Version Date of Issue
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Section B Changed Classes/Guidelines Final Version Date of issue: 19th December 2020 1 A2B ANTIULCERANTS r2020 Combinations of specific antiulcerants with other substances, such as anti- infectives against Helicobacter pylori, antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1. A2B1 H2 antagonists R2002 Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. A2B2 Proton pump inhibitors r2021 Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro- oesophageal disease or similar conditions are classified here. Includes potassium- competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc. A2B3 Prostaglandin antiulcerants Includes misoprostol, enprostil. A2B4 Bismuth antiulcerants Includes combinations with antacids. A2B9 All other antiulcerants r2020 Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to
    [Show full text]